نتائج البحث - David R. Macdonald

تنقيح النتائج
  1. 1
    Evidence for Consistency of the Glycation Gap in Diabetes

    Evidence for Consistency of the Glycation Gap in Diabetes حسب Ananth Nayak, Martin R. Holland, David R. Macdonald, Alan Nevill, Baldev Singh

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in Canada

    Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in Canada حسب Isabelle Fleury, David R. Macdonald, Mona Shafey, Anna Christofides, Laurie H. Sehn

    منشور في 2025
    احصل على النص الكامل
    Pré-impressão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

    Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy حسب Olivier Chinot, David R. Macdonald, Lauren E. Abrey, Gudrun Zahlmann, Yannick Kerloëguen, Timothy F. Cloughesy

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

    End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria حسب Martin J. van den Bent, Michael A. Vogelbaum, Patrick Y. Wen, David R. Macdonald, Susan M. Chang

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Response Assessment in Neuro-Oncology Clinical Trials

    Response Assessment in Neuro-Oncology Clinical Trials حسب Patrick Y. Wen, Susan M. Chang, Martin J. van den Bent, Michael A. Vogelbaum, David R. Macdonald, Eudocia Q. Lee

    منشور في 2017
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Canadian Recommendations for the Treatment of Glioblastoma Multiforme

    Canadian Recommendations for the Treatment of Glioblastoma Multiforme حسب Warren Mason, Rolando F. Del Maestro, David D. Eisenstat, Peter Forsyth, Dorcas Fulton, Normand Laperrière, David R. Macdonald, James Perry, Brian Thiessen

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme

    Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme حسب Jacob C. Easaw, Warren Mason, James Perry, Normand Laperrière, David D. Eisenstat, Rolando F. Del Maestro, K. Bélanger, Dorcas Fulton, David R. Macdonald

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Survey of treatment recommendations for anaplastic oligodendroglioma

    Survey of treatment recommendations for anaplastic oligodendroglioma حسب Lauren E. Abrey, David N. Louis, Nina A. Paleologos, Andrew B. Lassman, Jeffrey J. Raizer, Warren Mason, Jonathan L. Finlay, David R. Macdonald, Lisa M. DeAngelis, J. Gregory Cairncross

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas

    Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas حسب J. Gregory Cairncross, Keisuke Ueki, Magdelena C. Zlatescu, David K. Lisle, Dianne M. Finkelstein, Robert Hammond, Jonathan S. Silver, Paul C. Stark, David R. Macdonald, Yasushi Ino, David A. Ramsay, David N. Louis

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131

    Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 حسب Michael A. Vogelbaum, Brian Berkey, David M. Peereboom, David R. Macdonald, Caterina Giannini, John H. Suh, Robert B. Jenkins, James G. Herman, Paul D. Brown, Deborah T. Blumenthal, Christopher Biggs, Christopher J. Schultz, Minesh P. Mehta

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

    Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma حسب Michael Weller, Thierry Gorlia, J. G. Cairncross, Martin J. van den Bent, Warren Mason, K. Bélanger, Alba A. Brandes, Ulrich Bogdahn, David R. Macdonald, Peter Forsyth, Andrea O. Rossetti, Denis Lacombe, R.O. Mirimanoff, Charles J. Vecht, Roger Stupp

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Phase II study of PX-866 in recurrent glioblastoma

    Phase II study of PX-866 in recurrent glioblastoma حسب Marshall Pitz, Elizabeth A. Eisenhauer, Mary MacNeil, Brian Thiessen, Jacob C. Easaw, David R. Macdonald, David D. Eisenstat, Ankineedu Saranya Kakumanu, Muhammad Salim, Haji Chalchal, Jeremy A. Squire, Ming‐Sound Tsao, Suzanne Kamel‐Reid, Shantanu Banerji, Dongsheng Tu, Jean Powers, Diana F. Hausman, Warren Mason

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine–DNA Methyltransferase Biomarker Analyses

    Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Ef... حسب Timothy F. Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, Lawrence D. Recht, Alba A. Brandes, Estela Pineda, Tom Mikkelsen, Olivier Chinot, Carmen Balañá, David R. Macdonald, Manfred Westphal, Kirsten Hopkins, Michael Weller, Carlos Bais, Thomas Sandmann, Jean-Marie Bruey, Hartmut Koeppen, Bo Liu, Wendy Verret, S. Phan, David S. Shames

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group

    Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group حسب Nils D. Arvold, Terri S. Armstrong, Katherine E. Warren, Susan M. Chang, Lisa M. DeAngelis, Jaishri O. Blakeley, Marc C. Chamberlain, Erin Dunbar, Herbert H. Loong, David R. Macdonald, David A. Reardon, Michael A. Vogelbaum, Ying Yuan, Michael Weller, Martin J. van den Bent, Patrick Y. Wen

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Clinical trial end points for high-grade glioma: the evolving landscape

    Clinical trial end points for high-grade glioma: the evolving landscape حسب D. A. Reardon, E. Galanis, John DeGroot, Timothy F. Cloughesy, Jeffrey S. Wefel, Kathleen R. Lamborn, A. B. Lassman, Mark R. Gilbert, John H. Sampson, Wolfgang Wick, Marc C. Chamberlain, David R. Macdonald, Minesh P. Mehta, Michael A. Vogelbaum, Shannon Chang, Martin J. van den Bent, Patrick Y. Wen

    منشور في 2011
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group حسب Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. van den Bent, Susan M. Chang

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

    Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors حسب Andrew B. Lassman, Khê Hoang‐Xuan, Mei‐Yin C. Polley, Alba A. Brandes, J. Gregory Cairncross, Johan M. Kros, Lynn S. Ashby, Martin Taphoorn, Luís Souhami, Winand N.M. Dinjens, Nadia N. Laack, Mathilde C.M. Kouwenhoven, Karen Fink, Pim J. French, David R. Macdonald, Denis Lacombe, Minhee Won, Thierry Gorlia, Minesh P. Mehta, Martin J. van den Bent

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

    The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria حسب Lakshmi Nayak, Lisa M. DeAngelis, Alba A. Brandes, David M. Peereboom, Evanthia Galanis, Nancy U. Lin, Riccardo Soffietti, David R. Macdonald, Marc C. Chamberlain, James Perry, Kurt A. Jaeckle, Minesh P. Mehta, Roger Stupp, Alona Muzikansky, Elena Pentsova, Timothy F. Cloughesy, Fábio M. Iwamoto, J. C. Tonn, Michael A. Vogelbaum, Patrick Y. Wen, Martin J. van den Bent, David A. Reardon

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Association of<i>MGMT</i>Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide

    Association of<i>MGMT</i>Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide حسب Erica H. Bell, Peixin Zhang, Barbara J. Fisher, David R. Macdonald, Joseph P. McElroy, Glenn J. Lesser, Jessica L. Fleming, Arup Chakraborty, Ziyan Liu, Aline Paixão Becker, Denise Fabian, Kenneth Aldape, Lynn S. Ashby, Maria Werner‐Wasik, Eleanor Walker, Jean-Paul Bahary, Young Kwok, Ya-Yu Tsai, Nadia N. Laack, Christopher J. Schultz, Heidi J. Gray, H. Ian Robins, Minesh P. Mehta, Arnab Chakravarti

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults حسب Patrick Y. Wen, Martin J. van den Bent, Gilbert Youssef, Timothy F. Cloughesy, Benjamin M. Ellingson, Michael Weller, Evanthia Galanis, Daniel P. Barboriak, John de Groot, Mark R. Gilbert, Raymond Y. Huang, Andrew B. Lassman, Minesh P. Mehta, Annette M. Molinaro, Matthias Preusser, Rifaquat Rahman, Lalitha Shankar, Roger Stupp, Javier Villanueva-Meyer, Wolfgang Wick, David R. Macdonald, David A. Reardon, Michael A. Vogelbaum, Susan M. Chang

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: